TLPH
Talphera, Inc.
Drug Manufacturers - Specialty & Generic
Market Cap$43M
5Y Perf.-96.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TLPH vs NKTR
Revenue, margins, valuation, and 5-year total return — side by side.
NKTR
Nektar Therapeutics
Biotechnology
Market Cap$1.69B
5Y Perf.-74.4%
TLPH vs NKTR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TLPH | NKTR |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $43M | $1.69B |
| Revenue (TTM) | $28K | $55M |
| Net Income (TTM) | $-14M | $-164M |
| Gross Margin | -40.8% | 99.6% |
| Operating Margin | -481.6% | -237.9% |
| Total Debt | $0.00 | $149M |
| Cash & Equiv. | $6M | $15M |
TLPH vs NKTR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TLPH
NKTR
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Talphera, Inc. (TLPH) | 100 | 3.2 | -96.8% |
| Nektar Therapeutics (NKTR) | 100 | 25.6 | -74.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TLPH vs NKTR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TLPH leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Nektar Therapeutics is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
TLPH
Talphera, Inc.
The Income Pick
TLPH carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.10
- EPS growth 32.0%
- Lower volatility, beta 1.10, current ratio 5.49x
Best for: income & stability and growth exposure
NKTR
Nektar Therapeutics
The Long-Run Compounder
NKTR is the clearest fit if your priority is long-term compounding.
- -59.1% 10Y total return vs TLPH's -98.6%
- -297.1% margin vs TLPH's -510.4%
- +8.2% vs TLPH's +70.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TLPH | -18.2% revenue growth vs NKTR's -43.9% |
| Quality / Margins | NKTR | -297.1% margin vs TLPH's -510.4% |
| Stability / Safety | TLPH | Beta 1.10 vs NKTR's 1.85 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NKTR | +8.2% vs TLPH's +70.5% |
| Efficiency (ROA) | TLPH | -62.2% ROA vs NKTR's -62.8%, ROIC -120.3% vs -57.2% |
TLPH vs NKTR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
TLPH vs NKTR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNKTRLAGGINGTLPH
TLPHTalphera, Inc.
1leads
NKTRNektar Therapeutics
3leads
6 Total Categories
CATEGORYLEADERvs TLPHMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NKTR4/5
Valuation MetricsMultiples, price ratios, and targets
NKTR2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TLPH5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
NKTR6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NKTR leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
NKTR is the larger business by revenue, generating $55M annually — 1972.6x TLPH's $28,000. NKTR is the more profitable business, keeping -3.0% of every revenue dollar as net income compared to TLPH's -510.4%.
| Metric | TLPHTalphera, Inc. | NKTRNektar Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $28,000 | $55M |
| EBITDAEarnings before interest/tax | -$11M | -$130M |
| Net IncomeAfter-tax profit | -$14M | -$164M |
| Free Cash FlowCash after capex | -$11M | -$209M |
| Gross MarginGross profit ÷ Revenue | -40.8% | +99.6% |
| Operating MarginEBIT ÷ Revenue | -481.6% | -2.4% |
| Net MarginNet income ÷ Revenue | -510.4% | -3.0% |
| FCF MarginFCF ÷ Revenue | -405.9% | -3.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -25.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +56.1% | -4.5% |
NKTR leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
NKTR leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | TLPHTalphera, Inc. | NKTRNektar Therapeuti… |
|---|---|---|
| Market CapShares × price | $43M | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $37M | $1.8B |
| Trailing P/EPrice ÷ TTM EPS | -2.58x | -8.57x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1547.32x | 30.64x |
| Price / BookPrice ÷ Book value/share | 2.19x | 15.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
NKTR leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
TLPH leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
TLPH delivers a -118.0% return on equity — every $100 of shareholder capital generates $-118 in annual profit, vs $-4 for NKTR. On the Piotroski fundamental quality scale (0–9), TLPH scores 4/9 vs NKTR's 2/9, reflecting mixed financial health.
| Metric | TLPHTalphera, Inc. | NKTRNektar Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -118.0% | -4.0% |
| ROA (TTM)Return on assets | -62.2% | -62.8% |
| ROICReturn on invested capital | -120.3% | -57.2% |
| ROCEReturn on capital employed | -65.0% | -55.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | — | 1.66x |
| Net DebtTotal debt minus cash | -$6M | $134M |
| Cash & Equiv.Liquid assets | $6M | $15M |
| Total DebtShort + long-term debt | $0 | $149M |
| Interest CoverageEBIT ÷ Interest expense | — | -4.74x |
TLPH leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
NKTR leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NKTR five years ago would be worth $2,765 today (with dividends reinvested), compared to $385 for TLPH. Over the past 12 months, NKTR leads with a +818.2% total return vs TLPH's +70.5%. The 3-year compound annual growth rate (CAGR) favors NKTR at 93.3% vs TLPH's 5.9% — a key indicator of consistent wealth creation.
| Metric | TLPHTalphera, Inc. | NKTRNektar Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -24.3% | +92.0% |
| 1-Year ReturnPast 12 months | +70.5% | +818.2% |
| 3-Year ReturnCumulative with dividends | +18.7% | +621.8% |
| 5-Year ReturnCumulative with dividends | -96.1% | -72.3% |
| 10-Year ReturnCumulative with dividends | -98.6% | -59.1% |
| CAGR (3Y)Annualised 3-year return | +5.9% | +93.3% |
NKTR leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TLPH and NKTR each lead in 1 of 2 comparable metrics.
Risk & Volatility
TLPH is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than NKTR's 1.85 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NKTR currently trades 76.5% from its 52-week high vs TLPH's 55.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TLPHTalphera, Inc. | NKTRNektar Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.10x | 1.85x |
| 52-Week HighHighest price in past year | $1.57 | $109.00 |
| 52-Week LowLowest price in past year | $0.38 | $7.99 |
| % of 52W HighCurrent price vs 52-week peak | +55.9% | +76.5% |
| RSI (14)Momentum oscillator 0–100 | 55.7 | 53.4 |
| Avg Volume (50D)Average daily shares traded | 164K | 991K |
Evenly matched — TLPH and NKTR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | TLPHTalphera, Inc. | NKTRNektar Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $132.83 |
| # AnalystsCovering analysts | — | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NKTR leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). TLPH leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallNektar Therapeutics (NKTR)Leads 3 of 6 categories
Loading custom metrics...
TLPH vs NKTR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TLPH or NKTR a better buy right now?
Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TLPH or NKTR?
Over the past 5 years, Nektar Therapeutics (NKTR) delivered a total return of -72.
3%, compared to -96. 1% for Talphera, Inc. (TLPH). Over 10 years, the gap is even starker: NKTR returned -59. 1% versus TLPH's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TLPH or NKTR?
By beta (market sensitivity over 5 years), Talphera, Inc.
(TLPH) is the lower-risk stock at 1. 10β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 68% more volatile than TLPH relative to the S&P 500.
04Which is growing faster — TLPH or NKTR?
On earnings-per-share growth, the picture is similar: Talphera, Inc.
grew EPS 32. 0% year-over-year, compared to -12. 1% for Nektar Therapeutics. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TLPH or NKTR?
Nektar Therapeutics (NKTR) is the more profitable company, earning -297.
1% net margin versus -510. 4% for Talphera, Inc. — meaning it keeps -297. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NKTR leads at -236. 8% versus -481. 6% for TLPH. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TLPH or NKTR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TLPH or NKTR better for a retirement portfolio?
For long-horizon retirement investors, Talphera, Inc.
(TLPH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10)). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TLPH: -98. 6%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TLPH and NKTR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.